Related references
Note: Only part of the references are listed.Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li et al.
CANCER BIOLOGY & THERAPY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report
Ian F. Pollack et al.
NEURO-ONCOLOGY (2007)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
D. Hagerstrand et al.
ONCOGENE (2006)
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
Erin R. Gardner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
G Dresemann
ANNALS OF ONCOLOGY (2005)
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target:: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij et al.
EUROPEAN JOURNAL OF CANCER (2003)
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux
HQ Dai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
MJ van den Bent et al.
ANNALS OF ONCOLOGY (2003)
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
E Raymond et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
C Twelves et al.
ANNALS OF ONCOLOGY (2002)
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo
C Dai et al.
GENES & DEVELOPMENT (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Control of progenitor cell number by mitogen supply and demand
P van Heyningen et al.
CURRENT BIOLOGY (2001)
Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features
JS Smith et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2000)
Share Paper
